首页> 外文期刊>Iranian Journal Of Allergy, Asthma and Immunology >CbpM and CbpG of Streptococcus Pneumoniae Elicit a High Protection in Mice Challenged with a Serotype 19F Pneumococcus
【24h】

CbpM and CbpG of Streptococcus Pneumoniae Elicit a High Protection in Mice Challenged with a Serotype 19F Pneumococcus

机译:肺炎链球菌的CbpM和CbpG激发小鼠血清型19F肺炎球菌的高度保护。

获取原文
       

摘要

Among many pneumococcal antigens, choline-binding proteins (CPBs) display a high immunogenicity in animal models. This study aims to determine the immunogenicity of CbpM, CbpG and CbpL proteins of Streptococcus pneumoniae in a mice model. The genes were cloned into p ET21a expression vector and the recombinant proteins were produced. Mice were immunized with the purified recombinant proteins. Subsequently, the mice were challenged with S. pneumoniae ATCC 49619 (2×106 CFU) and their survival and bacterial clearances were followed 24 hours after infection. The antibody responses of the mice were determined by ELISA assay. The opsonophagocytosis assay was performed using rabbit’s sera. Passive immunization was carried out using two doses of anti-CbPs antibodies. Finally, these mice were experimentally infected with virulent bacteria and the protective effects of two doses of 10 and 100 μg/mL by monitoring the survival rate and bacterial clearance were determined at 2, 3 and 7 days after bacterial challenge. The mice actively immunized with CbpM, CbpG and CbpL recombinant proteins showed survival rate of 100%, 85% and 75%, respectively. The survival rates among passively immunized mice groups which received 100 μg/mL dose of anti-CbpM, anti-CbpG and anti- CbpL were 50%, 50% and 25%, respectively. The rates of opsonization with rabbit’s antibodies against CbpM, CbpG, and CbpL at 100 μg/mL doses was 45.6%, 14.7% and 82.3%, and at 10 μg/mL was 12.9%, 12.2% and 9.35%, respectively.?Our findings suggest that the recombinant proteins particularly CbpM and CbpG can protect the mice against pneumococcus19F serotype and effectively induce a protective antibody response. Thus, CbpG and CbpM proteins might be used as suitable vaccine candidate in pneumococcal vaccine formulations.
机译:在许多肺炎球菌抗原中,胆碱结合蛋白(CPB)在动物模型中显示出很高的免疫原性。这项研究旨在确定肺炎链球菌CbpM,CbpG和CbpL蛋白在小鼠模型中的免疫原性。将基因克隆到p ET21a表达载体中,并产生重组蛋白。用纯化的重组蛋白免疫小鼠。随后,用肺炎链球菌ATCC 49619(2×106 CFU)攻击小鼠,并在感染后24小时追踪其存活和细菌清除率。通过ELISA测定确定小鼠的抗体应答。使用兔血清进行调理吞噬作用测定。使用两剂抗CbPs抗体进行被动免疫。最后,对这些小鼠进行实验性感染,并在细菌攻击后第2、3和7天通过监测存活率和细菌清除率,确定两种剂量的10和100μg/ mL的保护作用。用CbpM,CbpG和CbpL重组蛋白主动免疫的小鼠的存活率分别为100%,85%和75%。接受100μg/ mL剂量的抗CbpM,抗CbpG和抗CbpL的被动免疫小鼠组的存活率分别为50%,50%和25%。在100μg/ mL剂量下,兔抗CbpM,CbpG和CbpL抗体调理作用的发生率分别为45.6%,14.7%和82.3%,在10μg/ mL的情况下分别为12.9%,12.2%和9.35%。研究结果表明,重组蛋白特别是CbpM和CbpG可以保护小鼠免受肺炎球菌19F血清型的侵害,并有效诱导保护性抗体应答。因此,CbpG和CbpM蛋白可用作肺炎球菌疫苗制剂中的合适候选疫苗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号